CSL (ASX:CSL) - Cotización, noticias y análisis

Resumen de acción CSL

CSL Limited investiga, desarrolla, fabrica, comercializa y distribuye productos biofarmacéuticos y vacunas en Australia, Estados Unidos, Alemania, Reino Unido, Suiza, China y a escala internacional.

Acerca de la empresa

CSL fundamental analysis
Snowflake Score
Valuation	3/6
Future Growth	3/6
Past Performance	4/6
Financial Health	4/6
Dividends	0/6

Recompensas

Cotiza un 21% por debajo de nuestra estimación de su valor justo

Se prevé un crecimiento anual de los beneficios de 14.72%

Los beneficios aumentaron un 16.7% el pasado año

Análisis de riesgos

Tiene un alto nivel de endeudamiento

Competidores de CSL Limited

Clinuvel Pharmaceuticals

ASX:CUV

AU$730.1m

Vertex Pharmaceuticals

NasdaqGS:VRTX

US$102.7b

Regeneron Pharmaceuticals

NasdaqGS:REGN

US$95.3b

Gilead Sciences

NasdaqGS:GILD

US$81.6b

Historial de precios y rendimiento

Summary of all time highs, changes and price drops for CSL
Historical stock prices
Current Share Price	AU$273.30
52 Week High	AU$312.99
52 Week Low	AU$228.65
Beta	0.29
1 Month Change	-5.08%
3 Month Change	-6.72%
1 Year Change	-9.08%
3 Year Change	0.79%
5 Year Change	36.74%
Change since IPO	34,062.84%

Noticias y actualizaciones recientes

Does CSL (ASX:CSL) Have A Healthy Balance Sheet?

Mar 19

Recent updates

CSL Limited's (ASX:CSL) Intrinsic Value Is Potentially 47% Above Its Share Price

Aug 13

CSL (ASX:CSL) Has A Pretty Healthy Balance Sheet

May 30

A Look At The Intrinsic Value Of CSL Limited (ASX:CSL)

May 09

Does CSL (ASX:CSL) Have A Healthy Balance Sheet?

Mar 01

Estimating The Fair Value Of CSL Limited (ASX:CSL)

Feb 07

CSL (ASX:CSL) Seems To Use Debt Quite Sensibly

Nov 17

CSL Limited (ASX:CSL) Shares Could Be 24% Below Their Intrinsic Value Estimate

Oct 27

We Think CSL (ASX:CSL) Can Stay On Top Of Its Debt

Aug 19

Is CSL Limited (ASX:CSL) Trading At A 22% Discount?

Jul 29

CSL's (ASX:CSL) Problems Go Beyond Weak Profit

Feb 22

Is CSL Limited (ASX:CSL) Worth AU$270 Based On Its Intrinsic Value?

Jan 19

With EPS Growth And More, CSL (ASX:CSL) Is Interesting

Dec 08

CSL (ASX:CSL) Seems To Use Debt Quite Sensibly

Oct 26

We Think Shareholders Will Probably Be Generous With CSL Limited's (ASX:CSL) CEO Compensation

Oct 05

Here's Why We Think CSL (ASX:CSL) Is Well Worth Watching

Sep 02

CSL Limited (ASX:CSL) Shares Could Be 30% Above Their Intrinsic Value Estimate

Jul 22

CSL (ASX:CSL) Has A Pretty Healthy Balance Sheet

Jul 01

Do CSL's (ASX:CSL) Earnings Warrant Your Attention?

May 20

We Think CSL (ASX:CSL) Can Stay On Top Of Its Debt

Mar 29

Rentabilidad de los accionistas

	CSL	AU Biotechs	Mercado AU
7D	1.4%	1.9%	0.03%
1Y	-9.1%	-8.1%	4.2%

Rentabilidad vs. Industria: CSL igualó al sector Australian Biotechs , que obtuvo un rendimiento del -8.1% el año pasado.

Rentabilidad vs. Mercado: CSL obtuvo unos resultados inferiores a los del mercado Australian, que fue del 3.9% el año pasado.

Volatilidad de los precios

Is CSL's price volatile compared to industry and market?
CSL volatility
CSL Average Weekly Movement	2.6%
Biotechs Industry Average Movement	11.7%
Market Average Movement	9.0%
10% most volatile stocks in AU Market	17.7%
10% least volatile stocks in AU Market	3.5%

Precio estable de las acciones: CSL no ha tenido una volatilidad de precios significativa en los últimos 3 meses.

Volatilidad a lo largo del tiempo: La volatilidad semanal de CSL (3%) se ha mantenido estable durante el año pasado.

Acerca de la empresa

Fundada	Empleados	CEO	Página web
1916	32,065	Paul McKenzie	www.csl.com.au

CSL Limited investiga, desarrolla, fabrica, comercializa y distribuye productos biofarmacéuticos y vacunas en Australia, Estados Unidos, Alemania, Reino Unido, Suiza y China. La empresa opera a través de los segmentos CSL Behring, CSL Seqirus y CSL Vifor. El segmento CSL Behring ofrece productos plasmáticos, terapias génicas y recombinantes.

Resumen de fundamentos de CSL Limited

¿Cómo se comparan los beneficios e ingresos de CSL con su capitalización de mercado?
Estadísticas fundamentales de CSL
Capitalización bursátil	AU$132.07b
Beneficios(TTM)	AU$3.78b
Ingresos (TTM)	AU$21.70b

34.9x

Ratio precio-beneficio (PE)

6.1x

Ratio precio-ventas (PS)

¿Está CSL sobrevalorada?

Ver valor justo y análisis de valoración

Beneficios e Ingresos

Estadísticas clave de rentabilidad del último informe de resultados (TTM)
Cuenta de resultados (TTM) de CSL
Ingresos	US$14.18b
Coste de los ingresos	US$6.86b
Beneficio bruto	US$7.32b
Otros gastos	US$4.85b
Beneficios	US$2.47b

Últimos beneficios comunicados

Dec 31, 2023

Próxima fecha de beneficios

Aug 13, 2024

Beneficios por acción (BPA)	5.12
Margen bruto	51.63%
Margen de beneficio neto	17.43%
Ratio deuda/patrimonio	54.4%

¿Cómo se ha desempeñado CSL a largo plazo?

Ver rendimiento histórico y comparativa

Dividendos

1.3%

Rentabilidad actual por dividendo

48%

Ratio de pagos

Resumen de acción CSL

Recompensas

Análisis de riesgos

Competidores de CSL Limited

ASX:CUV

AU$730.1m

NasdaqGS:VRTX

US$102.7b

NasdaqGS:REGN

US$95.3b

NasdaqGS:GILD

US$81.6b

Historial de precios y rendimiento

Noticias y actualizaciones recientes

CSL Vifor and Travere Therapeutics Announces European Commission Approves FILSPARI® (sparsentan) for the Treatment of IgA Nephropathy

Does CSL (ASX:CSL) Have A Healthy Balance Sheet?

Now 20% undervalued

CSL Seqirus Confirms Full Preparation to Implement the Fda's Vaccines and Related Biological Products Advisory Committee

Upcoming dividend of US$1.19 per share

First half dividend of US$1.19 announced

Recent updates

CSL Vifor and Travere Therapeutics Announces European Commission Approves FILSPARI® (sparsentan) for the Treatment of IgA Nephropathy

Does CSL (ASX:CSL) Have A Healthy Balance Sheet?

Now 20% undervalued

CSL Seqirus Confirms Full Preparation to Implement the Fda's Vaccines and Related Biological Products Advisory Committee

Upcoming dividend of US$1.19 per share

First half dividend of US$1.19 announced

First half 2024 earnings: EPS misses analyst expectations

CSL Limited Announces Estimate Distribution for the Six Months Ended December 31, 2023, Payable on April 3, 2024

CSL Announces Top-Line Results from the Phase 3 AEGIS-II Trial Evaluating the Efficacy and Safety of CSL112 (apolipoprotein A-I (Human)

Now 22% undervalued

CSL Limited's (ASX:CSL) Earnings Haven't Escaped The Attention Of Investors

Now 21% undervalued

CSL and Arcturus Therapeutics' ARCT-154 Demonstrates Non-Inferiority to Original Strain and Superior Immunogenicity to Omicronba BA.4/5 Variant Compared to First-Generation mRNA Vaccine Booster Booster

CSL Limited to Report Fiscal Year 2024 Results on Jul 30, 2024

CSL Behring's HEMGENIX (Etranacogene Dezaparvovec-Drlb) Demonstrates At Three Years Post-T Treatment Long-Term Durability, Safety and Greater Bleed Protection Versus Prophylactic Treatment in People Living with Hemophilia B

Is CSL (ASX:CSL) Using Too Much Debt?

Japan's Ministry of Health, Labour and Welfare Approves CSL and Arcturus Therapeutics' ARCT-154, the First Self-Amplifying mRNA Vaccine Approves for COVID in Adults

CSL Limited (ASX:CSL) Shares Could Be 28% Below Their Intrinsic Value Estimate

Health Canada Authorizes Csl's Hemgenix(R) (Etranacogene Dezaparvovec) as First Gene Therapy for Hemophilia B

CSL Limited Reaffirms Financial Outlook for Fiscal Year 2024

CSL Seqirus Announces Data from Three Studies Supporting the Clinical, Public Health Benefit and Cost Savings Associated with Cell-Based and Adjuvanted Influenza Vaccines

CSL Seqirus Shares Data Demonstrating the Potential for Influenza Vaccination to Reduce the Burden on Healthcare Resources

These 4 Measures Indicate That CSL (ASX:CSL) Is Using Debt Reasonably Well

Arcturus Therapeutics Holdings Inc. and Csl Seqirus Announce European Medicines Agency Validates Marketing Authorization Application for Arct-154 Vaccine to Prevent Covid-19

Upcoming dividend of US$1.29 per share at 1.4% yield

Independent Non-Executive Chairman recently sold AU$5.6m worth of stock

CSL Appoints Jeffrey Ball as First Chief Sustainability Officer

CSL Limited, Annual General Meeting, Oct 09, 2024

Full year 2023 earnings: EPS misses analyst expectations

CSL Limited's (ASX:CSL) Intrinsic Value Is Potentially 47% Above Its Share Price

CSL Limited to Report Fiscal Year 2023 Results on Aug 15, 2023

CSL (ASX:CSL) Has A Pretty Healthy Balance Sheet

A Look At The Intrinsic Value Of CSL Limited (ASX:CSL)

Upcoming dividend of US$1.07 per share at 1.1% yield

Does CSL (ASX:CSL) Have A Healthy Balance Sheet?

First half 2023 earnings released: EPS: US$3.37 (vs US$3.85 in 1H 2022)

CSL Limited Announces Interim Dividend, Payable on 5 April 2023

Estimating The Fair Value Of CSL Limited (ASX:CSL)

CSL Limited, Annual General Meeting, Oct 11, 2023

CSL Limited to Report First Half, 2023 Results on Feb 14, 2023

SAB Biotherapeutics Novel DiversitAb™ Platform Proven to Develop Anti-idiotype Antibodies to Help Treat Autoimmune Diseases

CSL Limited Announces Management Changes

CSL Limited Announces Chief Executive Officer Changes

CSL Limited Announces FDA Approval of First Gene Therapy for Adults with Hemophilia B

CSL (ASX:CSL) Seems To Use Debt Quite Sensibly

CSL Limited (ASX:CSL) Shares Could Be 24% Below Their Intrinsic Value Estimate

Independent Non Executive Director recently bought AU$74k worth of stock

Consensus forecasts updated

Now 20% undervalued

CSL Limited Announces Positive Preclinical Data for Self-Amplifying Messenger RNA (sa-mRNA) Influenza Vaccine Candidates

Now 20% undervalued

MD, CEO & Executive Director exercised options and sold AU$4.7m worth of stock

Non-Independent Non-Executive Director recently sold AU$6.4m worth of stock

Upcoming dividend of US$1.18 per share

Non-Independent Non-Executive Director exercised options to buy AU$11m worth of stock.

We Think CSL (ASX:CSL) Can Stay On Top Of Its Debt

CSL Limited Announces Positive Top-Line Phase 3 Results for Garadacimab as Preventive Treatment in Patients with Hereditary Angioedema (HAE)

Full year 2022 earnings: EPS in line with expectations, revenues disappoint

CSL Limited Announces Final Dividend for the Period Ended June 30, 2022, Payable on 6 September 2022